Beam Therapeutics is trading 7.3% up now at $28.51, most likely reflecting biotech-sector momentum after Moderna’s positive personalized cancer-vaccine trial results lifted sentiment across biotechnology and mRNA-related names.
- No clear company-specific announcement was identified for August 19, 2026.
- The latest company release was published August 4 and contained no event or analyst action dated August 19.
- Biotech is up 3.73%; this is a sector-driven explanation rather than a Beam-specific catalyst.